Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You must get over this obsession you have with me ;o)
Thats a must for me Trench
I tend to disregard disproportionate movements on small volumes. You have to remember that a lot of holders on AIM these days are very nervous and don't invest longer term
Be good to see Dr Peter Sargent buy a decent chunk of shares now the interim figures have been released. That would send out a positive message to the market
DeBull that is an interesting article
GCSF is a widely used and very expensive drug. JM mentions in one of his presentations that the tool PYC is working on developing is aimed at providing guidance to clinicians on the use of GCSF, as to when would be the right circumstances to use it and when not. This could potentially be valuable in terms of optimising the use of GCSF and potentially saving money and healthcare resources for payers
The Japanese company Kyowa Kirin’s product is a GCSF drug called GRAN. This works to ‘selectively increase the count of a type of white blood cell called neutrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy ..’
I assume that the tool PYC are developing could provide a more accurate basis and more costs effective way of prescribing GCSF than is already in the market place
The person( I assume gambler123) buys Monday 1st thing 117k and sell yesterday and 1st thing this morning
Strange
Some light reading.
https://www.linkedin.com/pulse/granulocyte-colony-stimulating-factor-g-csf-drugs-market/
The part of the article that i found interesting is "Another significant player in the market is Kyowa Kirin. This Japanese pharmaceutical company has a strong presence in the G-CSF drugs market with its product, Gran, which is used for the management of neutropenia." As far as i understand it, this is what PYC are striving for with the adaption of their dosing tool?
I did notice that Jim was rubbing his head a bit at times, but maybe he was not 100% on the day
His explanations were well thought through and meticulously explained, as has always been the case. I don't think Jim is the type to take offence and he still has so much to contribute to the business. He is still a key player here
I agree Trench
HeS made a big impact in just 6mths and I like his drive and control
Not sure how a natural speech defect can count against someone though..
Only issue i have is he does not pronounce his G's at the end of words!
Jim, looked tired and miffed, like he did not want to be at the Q&A
I think that by the time the next Q&A comes round, Peter will be flying solo.
Tweet showing Dr Sargent in front exhibitor board showing Physiomics name five times
I like this guy. He is confident and not afraid to make changes. Seems to have a clear plan for success. Good to see Peter and Jim working well together
The impatient from yesterday buys selling today .....thats all...its when the market pays you by surprise
But then sell a day later
The new permanent role was explained in Peters 3 part triangle diagram.. namely to have someone permanent to oversee the increased client work
As you say peter was excited about bio stats but also the dosing tool potential
Either no one asked about BOD buying shares, or they decided not to answer those questions?
I also found the reply about Hitesh interesting. Many will know that Hitesh is the principal consultant, but has many fingers in many pies. I take it from that, that they want someone who is 110% committed to the job & not having their time divided by System forcasting etc.
They seem genuinely excited about this Bio-statistics venture.
Particularly the 20-35min and the final 10 mins Q and a
Evening Jack
Everything today was a buy ...particularly the 1.3p and 1.34p ones
I don't post much but have quite a lot invested in PYC. I purchased another £584.05 worth of shares today at approx 11.30 am. It is showing as a sell?
More buys today than for weeks
Strange lack of trading following a positive presentation !!
Positive presentation. Sounds like plenty of deals reaching completion with pipeline up 50% and almost the same as entire mcap! Obviously desperate to say the shareprice is a joke but couldn't, lol. All buys today and can still buy at 1.3475p, but mm's scaring people off with the spread. Aimho.
Good Post Brighty
Agree in your statements - I mean the last presentation stated a £1m pipeline then the interims last week stated £1.5 m pipeline so it would indicate there is significant growth forecasted
The moment that Dr Peter Sargent joined PYC last year, first as CSO and now as CEO, conveyed a game changing moment for this little company. He's held senior management roles at global consultancy business Syneos Health Inc (NASDAQ: SYNH), & was Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK. He obviously liked what he saw at PYC and joined the company for a reason. 2024 looks a far more promising time to be invested in PYC as a result.
You would imagine from his track record that he's pretty well connected and has the ability to attract and negotiate much bigger contract awards than the previous regime. It will be interesting to hear how things are progressing at 12 Noon today.....
Good luck, Brighty
12.00 noon today
Good news, fake spread, can still buy at 1.375
Yes King
Also an outside we could maybe beat the expectations (Pyc said said would be met last week)
The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunitie